Abstract Luteinizing hormone/human chorionic gonadotropin stimulates progesterone biosynthesis in the corpus luteum by activating cyclic adenosine monophosphate/protein kinase A cascade. Recent studies have shown that cyclic adenosine monophosphate-mediated activation of protein kinase A interacts with the mammalian target of rapamycin signaling pathways. Furthermore, the use of mammalian target of rapamycin inhibitors for immunosuppression in transplant patients has shown adverse effects in reproductive functions. This study examined whether the mammalian target of rapamycin pathway plays any role in luteinizing hormone-mediated regulation of progesterone production. Human granulosa lutein cells were isolated from follicular aspirates of women undergoing in vitro fertilization. Cells were cultured for 72 h and treated with human chorionic gonadotropin (50 ng/ml) for different time periods with or without pretreatment with mammalian target of rapamycin complex 1 inhibitor, rapamycin, (20 nM) for 1 h. Expression of steroidogenic enzymes, including steroidogenic acute regulatory protein, cholesterol side chain cleavage enzyme, and 3β-hydroxysteroid dehydrogenase type 1 messenger RNA, were examined by real-time polymerase chain reaction after 6 h of human chorionic gonadotropin treatment. Expressions of phospho-ribosomal protein S6 kinase and cholesterol side chain cleavage enzyme were analyzed after 15 min and 24 h of human chorionic gonadotropin treatment, respectively. Progesterone production was analyzed by an enzyme immunoassay kit after human chorionic gonadotropin (50 ng/ml) or forskolin (10 μM) treatment for 24 h. Treatment with human chorionic gonadotropin increased the expression of downstream targets of mammalian target of rapamycin complex 1, as well as cholesterol side chain cleavage enzyme, 3β-hydroxysteroid dehydrogenase type 1 and steroidogenic acute regulatory protein messenger RNAs. These increases were inhibited by rapamycin pretreatment. Increased progesterone production in response to treatment with human chorionic gonadotropin or forskolin was also blocked by rapamycin pretreatment. Our findings support a role for mammalian target of rapamycin complex 1 in regulating steroidogenesis in human granulosa lutein cells.
Introduction
It has been well established that progesterone production in mammalian ovaries, including human, is regulated by the receptor-mediated activation of cyclic AMP production by luteinizing hormone (LH) [1] [2] [3] [4] . Cyclic AMP then activates protein kinase A (PKA), which culminates in increased progesterone production. The mechanism of increased progesterone production by cyclic AMP involves activation of multiple steps in steroidogenesis, including uptake of plasmaderived lipoprotein-associated cholesterol into the cytoplasm [5, 6] , steroidogenic acute regulatory protein (STAR)-mediated transport of cholesterol from cytosol to mitochondria [7] [8] [9] , and the movement of cholesterol from the outer to the inner mitochondrial membranes [10] [11] [12] where the initial reaction in steroidogenesis-the conversion of cholesterol to pregnenolone-occurs [13, 14] . It has also been well established that transcriptional activity of cholesterol side chain cleavage enzyme (CYP11A1) is increased in response to LH treatment [15] . These events culminate in increased transformation of cholesterol to pregnenolone, and subsequent conversion to progesterone, in the cytosol. At higher concentrations of LH/human chorionic gonadotropin (hCG), a second pathway involving Gq-mediated activation of phospholipase C has also been reported [16] [17] [18] [19] . More recent studies have revealed that the signaling pathways are more complex than previously recognized. For instance, in rodent ovaries, PKA can activate other kinases including ERK1/2 and Akt [20] [21] [22] . Akt is a known activator of mammalian target of rapamycin (mTOR), increasing transcriptional and translational events that lead to increased cell size and number [17, 23, 24] . Furthermore, we have shown that in rat ovarian thecainterstitial cells, LH can activate steroidogenic enzyme expression and androstenedione production via activation of the mTOR signaling pathway. mTOR is an atypical member of the PI-3 kinase family of serine/threonine kinases [25] [26] [27] [28] that plays a central role in mediating cell growth and proliferation [29] . Growth-promoting hormones have been recognized to activate mTOR via activation of the protein kinase Akt. The mechanism of mTOR activation uses a complex pathway. The mTOR kinase exists in two physically distinct protein complexes-mammalian target of rapamycin complex 1 (mTORC1) and mammalian target of rapamycin complex 2 (mTORC2). mTORC1 is composed of three essential components-mTOR, raptor, and mTST8-and is inhibited by rapamycin, whereas mTORC2 is insensitive to rapamycin [30] . Under unstimulated conditions, mTOR exists in an inactive state, which is maintained by the GDP-bound Rheb. Under hormonal stimulation, Rheb gets activated by conversion to the GTP-bound form, which then activates mTOR. In the activated state, mTOR phosphorylates downstream ribosomal proteins S6K1 and 4EBP1. These processes lead to activation of protein translation and increased transcription, culminating in cell growth, as well as in the regulation of metabolic pathways [27, 28] . Although the mTOR signaling pathway is well-recognized as regulating proliferative pathways, it can also exert regulatory roles in lipid synthesis and the regulation of metabolic pathways, including glycolysis [31, 32] . In this study, we examined the possible involvement of mTOR signaling in progesterone production by human granulosa lutein cells.
Materials and methods
McCoy's 5A medium and 0.4 % trypan blue were purchased from Invitrogen/GIBCO (Carlsbad, CA). Penicillinstreptomycin was purchased from Roche Diagnostics (Indianapolis, IN). BSA and anti-β-tubulin antibody were purchased from Sigma Chemical Co. (St. Louis, MO). Purified hCG was purchased from Dr. A.F. Parlow (National Hormone and Peptide Program, Torrance, CA). Forskolin was obtained from BIOMOL Research Laboratories (Plymouth Meeting, PA). Rapamycin, anti-mouse or anti-rabbit IgG horseradish peroxidase conjugates, anti-p-S6K1, and anti-S6K1 antibodies were purchased from Cell Signaling Technology (Beverly, MA). Anti-CYP11A1 was obtained from Abcam (Cambridge, MA). Femto Super Signal Chemiluminescence reagent and Restore stripping buffer were purchased from Pierce (Rockford, IL). Progesterone enzyme immunoassay (EIA) kit was purchased from Cayman Chemical (Ann Arbor, MI). Real-time polymerase chain reaction (PCR) reagents, as well as the primers and probes for STAR (assay id: Hs00264912_m1), CYP11A1 (assay id: Hs00167984_m1), 3β-hydroxysteroid dehydrogenase type 1 (HSD3B1) (assay id: Hs01084547_gH), and 18S rRNA (assay id: Hs99999901_s1) were purchased from Applied Biosystems (Foster City, CA). All other reagents used were conventional commercial products.
Granulosa lutein cell isolation and culture
Human granulosa lutein cells were isolated from follicular aspirates obtained at the time of oocyte retrieval in women undergoing in vitro fertilization. In these women, ovulation had been induced by hCG injection following ovarian stimulation with recombinant human follicle-stimulating hormone (FSH) and LH. Follicles were aspirated 36 h after hCG administration and remaining aspirates were pooled after the oocytes had been isolated. The cell suspension was made free of red blood cells by centrifugation with FicollPaque PLUS, as previously described [33] . Briefly, the interface between the media and the Ficoll containing the granulosa cells was aspirated and resuspended in a fresh medium. The cells were washed twice to remove any residual blood cell contamination and resuspended in the final culture medium. Cell viability was tested by trypan blue dye exclusion [34] . The cells were then counted, plated, and cultured for 72 h to allow the granulosa cells to recover from LH receptor downregulation before further treatment with test substances.
Rapamycin effect on cell viability
To test the possible adverse effect of rapamycin on cell viability, cells were seeded into 12-well plates and cultured with McCoy's medium containing 10 % fetal bovine serum (FBS). The attached cells were serum-starved for 1 day and pretreated with 5, 10, 20, and 40 nM rapamycin dissolved in 3 µl of dimethyl sulfoxide (DMSO) for 1 h, followed by hCG (50 ng/ml) for 24 h. The control group received 3 µl of DMSO. After the treatment periods, cell viability was determined by Trypan Blue exclusion. Both the unstained (viable) and stained (nonviable) cells were counted and the percentages of viable cells were calculated.
Real-time PCR
After the different incubation periods, cells were harvested and total RNA was extracted using TRIzol reagent following manufacturer's instructions. Reverse transcription was carried out in a final volume of 20 μl containing 1 or 2 ug RNA, 2.5 μM random hexamer, 2 mM deoxynucleotide triphosphates, 5.5 mM MgCl 2 , 8 U ribonuclease inhibitor, and 25 U Multiscribe reverse transcriptase in a PTC-100 thermal controller. The resulting cDNA was diluted and subjected to real-time PCR reactions using predesigned primers and probes. The changes in gene expressions were calculated using the ΔΔCt method, with 18S rRNA as the internal control.
Western blot analysis
After various treatments, cell monolayers were washed with PBS and homogenized using a radio immunoprecipitation assay buffer (PBS containing 1 % Nonidet P-40, 0.5 % sodium deoxycholate, and 0.1 % sodium dodecyl sulfate). The protein content of the cell lysates were then determined. Samples (10-30 μg) were incubated with an SDS sample loading buffer and subjected to 10 % SDS-PAGE under reducing conditions, followed by Western blot analysis as previously described [35] . Briefly, membranes were blocked in 5 % fat-free milk for 1 h and then incubated overnight at 4°C with a primary antibody. After several washes with Tris-buffered saline containing Tween 20 (TBST), membranes were incubated in a peroxidase-conjugated secondary antibody for 1 h at room temperature. Following further washes with TBST, membrane-bound antibodies were detected using a chemiluminescence reagent. The total protein content of loading was monitored by reprobing the same blots with tubulin (loading control).
Assay of progesterone
To determine the involvement of the mTORC1 signaling pathway in hCG or forskolin-stimulated progesterone production, human granulosa cells were seeded in 35-mm plates with McCoy's medium containing 10 % FBS. After attachment, the cells were cultured for 72 h and pretreated with rapamycin (20 nM) for 1 h followed by treatment with hCG (50 ng/ml) or forskolin (10 μM), a pharmacological activator of adenylyl cyclase, for 24 h. At the end of the treatments, media were collected and progesterone was assayed using an EIA kit (Cayman, US) according to the manufacturer's instructions. Briefly, trace amounts of [ 3 H]-progesterone (10,000 cpm) were added to the media samples (500 μl) to monitor recovery of extraction. The media were then extracted with methylene chloride (3×) and suspended in the ELISA buffer, after evaporating methylene chloride. Fifty microliter of the sample or standard(s) were added to the wells of the ELISA plate and treated with Ellman's reagent followed by tracer (progesterone-acetylcholinesterase conjugate). After 60-90 min incubation in the dark, readings were taken at a wavelength of 412 nM using a plate reader. The progesterone values are expressed as pg/ml of the reconstituted extract. The extraction recovery of the assay was greater than 82 %. The assay has a range of 7.8-1000 pg/ml and sensitivity (80 % B/B 0 ) of approximately 10 pg/ml. The intra-assay and inter-assay coefficients of variation for progesterone were 4.9-54.5 % and 1.5-16.4 %, respectively.
Statistical analysis
Statistical analysis was carried out using one-way ANOVA, followed by the Tukey multiple comparison test. Values were considered statistically significant at P o 0.05. Each experiment was repeated at least 3 times, with similar results. Blots are representative of 3 experiments, and graphs represent the mean ± SE of three independent experiments.
Results

LH/hCG stimulates progesterone synthesis related gene expression
Prior to determining the role of mTOR signaling in hCGstimulated steroidogenic enzyme protein and messenger RNA (mRNA), the time course of hCG responsiveness on steroidogenic enzyme mRNA expression was determined. To test this, human granulosa lutein cells isolated from IVF retrieval fluids were cultured in the absence or presence of hCG for different time intervals, and the expression of CYP11A1, HSD3B1 and STAR mRNA were examined by real-time PCR. Experiments were performed in triplicate on each set of cells. In all samples, 50 ng/ml hCG treatment resulted in a time-dependent increase in the expression of steroidogenic enzymes HSD3B1, STAR, and CYP11A1. Representative results are shown in Fig. 1 . Levels of HSD3B1 increased 1.8-fold after 3 h of treatment with hCG and 2.5-fold after 6 h of treatment. Levels of CYP11A1 increased 2.1-fold after 3 h of treatment with hCG and 2.7-fold after 6 h of treatment. Levels of STAR increased 2.4-fold after 3 h of treatment with hCG and 4.2-fold after 6 h of treatment. Based on these results, 6-h incubation with 50 ng/ml of hCG was chosen for subsequent experiments.
HCG-stimulated progesterone synthesis related gene expression is blocked by the mTORC1 inhibitor
Since rapamycin is potentially toxic to the cells, initial experiments to determine the optimum dose of rapamycin that would produce no effect on cell viability revealed that a dose of 20 nM concentration of rapamycin produced no cell death. To test the role of mTORC1 signaling in LH/hCG action, granulosa lutein cells were pretreated with the mTORC1 inhibitor rapamycin (20 nM) for 1 h, followed by incubation with hCG for an additional 6 h. At the end of the incubation, the cells were processed for total RNA extraction and mRNA levels of steroidogenic enzymes (STAR, CYP11A1, and HSD3B1) were measured by real-time PCR. As shown in Figs. 2a-c, hCG treatment resulted in a significant increase in the levels of progesterone synthesis related genes (CYP11A1, HSD3B1, and STAR), while pretreatment with rapamycin blocked these increases. After establishing the inhibitory effect of rapamycin on hCGinduced expression of steroidogenic enzyme mRNA expression, the inhibitory effect of rapamycin was then tested on CYP11A1 protein expression in cell lysates after 24 h of incubation with hCG, by Western Blot analysis. The results presented in Fig. 2d show that hCG treatment produced a 4.6-fold increases in CYP11A1 protein, but pretreatment with rapamycin significantly reduced this increase. These results suggest that mTORC1 signaling is involved in hCG-induced steroidogenic enzyme expression. The results also show that rapamycin treatment at 20 nM concentration did not reduce cell viability compared to the control group without rapamycin (Fig. 3) .
Effect of hCG on mTOR signaling
The ability of hCG to activate mTOR signaling was then tested using the same dose that produced an increase in the expression of steroidogenic enzymes and mRNAs. Since the ribosomal protein S6 kinase is one of the important downstream targets of mTOR signaling [27, 28] , the effect of hCG on the formation of Phospho S6 kinase in human granulosa lutein cells was then determined. The cells were incubated with or without hCG for 6 h and the cell lysates were examined for p-S6K1 by Western Blot analysis. The results presented in Fig. 4 show that hCG treatment produced 8.7-fold increases in p-S6K1 formation. Pretreatment with rapamycin significantly reduced the stimulation produced by hCG. These results show that mTOR signaling pathway is operative in human granulosa lutein cells and that this pathway is activated by hCG. Thus, the blockade of hCG-stimulated activation of steroidogenic enzymes and mRNA in human granulosa lutein cells is consistent with a role of mTOR signaling pathway in hCG-mediated activation of steroidogenesis.
Rapamycin blocks LH/hCG or forskolin-stimulated progesterone synthesis
Primary cultures of human granulosa lutein cells were pretreated with or without rapamycin (20 nM) for 1 hr, followed by stimulation with hCG for 24 h. The incubation media were collected and progesterone levels were assayed as described in detail in the Methods. The results showed that, as seen in Fig. 5 , progesterone production, as expected, was increased more than 5-fold by hCG treatment compared to the control group. This pronounced increase was significantly reduced by pretreatment with rapamycin. Similarly, as shown in Fig. 6 , progesterone levels increased greater than 10-fold in forskolin-treated human granulosa lutein cells, but this increase was also significantly diminished by pretreatment with rapamycin, suggesting that the site of action of mTOR lies at a step after cyclic AMP production.
Discussion
Our study examined the hCG-stimulated signaling network involved in the regulation of steroidogenesis in human granulosa lutein cells. The results show that cultured human Fig. 1 HCG increases progesterone synthesis related gene expression in a time-dependent manner. Human granulosa lutein cells were incubated with hCG (50 ng/ml) for 0, 3, or 6 h. Cells were then harvested at different time periods for total RNA extraction followed by reverse transcription. The real-time PCR reactions were carried out using the diluted cDNA in triplicate with predesigned primers and probes for human STAR, CYP11A1, and HSD3B1, using 18S RNA as a control. *P o 0.05 vs. control granulosa lutein cells isolated from the retrieval fluids from follicles respond to hCG with increased expression of CYP11A1, HSD3B1, and STAR mRNA and protein. The extent of stimulation of CYP11A1 and HSD3B1 mRNA was comparable at 3 and 6 h of hCG treatment. The magnitude of responsiveness of STAR mRNA to hCG stimulation was higher (4.2-fold) than that seen for CYP11A1 (2.7-fold) and HSD3B1 (2.5-fold). The reason for differences in the extent of stimulation of mRNA and the corresponding protein for CYP11A1 and HSD3B1 is not understood although it could be attributed to the relatively higher instability of mRNA. The magnitude of progesterone response to hCG (5-fold) and forskolin (10-fold) was higher than that seen for the CYP11A1 and HSD3B1 mRNA transcripts. This difference could be partly due to longer incubation period (24 h) used for measuring progesterone response. It would also be possible that increased expression of STAR mRNA in Fig. 2 HCG-stimulated progesterone synthesis related gene expression is significantly reduced by pretreatment with rapamycin. Human granulosa lutein cells were incubated with hCG (50 ng/ml) with or without pretreatment with rapamycin (rapa; 20 nM) for 1 h. After 6 h of incubation with hCG, cells were harvested and total RNA was extracted and reverse transcribed into cDNA, which was subjected to real-time PCR reactions with predesigned primers and probes for human STAR (a), HSD3B1 (b), and CYP11A1 (c) using 18S RNA as a control. After 24 h of incubation, another set of cells were harvested, and CYP11A1 protein expression (d) was analyzed using Western Blot analysis. Protein loading was monitored by reprobing the same blots with tubulin antibody. *P o 0.05 vs. control, **P o 0.01 vs. hCG Fig. 3 Rapamycin treatment does not affect cell viability. Human granulosa lutein cells were incubated with hCG (50 ng/ml) with or without pretreatment with rapamycin (rapa; 20 nM) for 1 h. To test viability, the cells were harvested after 24 h of hCG and subjected to Trypan blue exclusion assay. NS-P 4 0.05 vs. control response to hCG treatment might contribute to increased progesterone production by facilitating cholesterol transport from outer to the inner mitochondrial membrane where cholesterol undergoes side chain cleavage to produce pregnenolone which is then converted to progesterone. Rapamycin reduced hCG-mediated increases in CYP11A1 protein 2-fold while reducing progesterone production 6-7-fold. This would suggest that rapamycin-mediated inhibition of STAR probably contributes more effectively to reduce progesterone production.
Since ovarian function is regulated by the anterior pituitary hormone LH and its placental counterpart hCG, previous studies have focused on the signaling pathways involved in the action of these two hormones through Gs protein-coupled receptors. While this is still true that both LH and hCG act primarily through interaction with Gscoupled signaling pathways [36] , the cyclic adenosine monophosphate (cAMP)-mediated responses might interact with other signaling pathways in granulosa cells. Here we present evidence showing that LH/hCG-mediated cAMP regulates progesterone production by interacting with the mTOR signaling pathway, since inhibition of mTOR signaling by rapamycin significantly reduced the expression of CYP11A1, as well as progesterone production. The inhibitory effect of rapamycin on progesterone synthesis was also seen when granulosa cells were treated with forskolin, an agent that increases cyclic AMP production, bypassing the LH/hCG receptor, which suggests that the site of the inhibitory action lies at a step after cyclic AMP production.
The mechanism by which cyclic AMP activates the mTOR signaling pathway is thought to occur via activation of Akt [23] . It has now been well established that Akt is the upstream activator of mTOR (reviewed in [37] ). Akt itself exists in an inactive form in most cells and signaling cascade emanating from hormones like insulin has been shown to activate inactive Akt to the active form by the PIP3-dependent protein kinase PDK1 [38] . It is possible that activation of PKA in response to LH/hCG stimulation in the ovary might prompt PDK1 to activate Akt. In fact, activation of Akt by FSH in the ovarian follicles has been previously reported [39, 40] . In our previous studies, we have shown that hCG can activate Akt in rat theca-interstitial cells and that this activation can be blocked by both PKA and Akt inhibitors [41] . Thus, it is conceivable that LH/ hCG-mediated activation of PKA might activate Akt via Fig. 4 HCG-induced phosphorylation of p-S6K1, the downstream target of mTOR signaling, is also significantly reduced by rapamycin pretreatment. Human granulosa lutein cells were incubated with or without rapamycin (rapa; 20 nM) for 1 h, followed by hCG (50 ng/ml) for 15 min. At the end of the incubation, the cells were harvested, and the p-S6K1 (lane 1) expression was analyzed using Western Blot analysis. Protein loading was monitored by reprobing the same blots with total S6k and tubulin antibodies (lanes 2 and 3). *P o 0.05 vs. control, **P o 0.01 vs. hCG Fig. 5 HCG-induced production of progesterone is significantly reduced by rapamycin pretreatment. Human granulosa lutein cells were treated with hCG (50 ng/ml) with or without pretreatment with rapamycin (rapa; 20 nM; for 1 h). After 24 h of hCG, progesterone production was determined by EIA as described in detail in the Methods. *P o 0.05 vs. control, **P o 0.01 vs. hCG Fig. 6 Forskolin-induced production of progesterone is significantly reduced by rapamycin pretreatment. Human granulosa lutein cells were pretreated with or without rapamycin (rapa; 20 nM) for 1 h, followed by treatment with forskolin (FSK; 10 μM), a pharmacological activator of adenylate cyclase, for 24 h. At the end of the treatments, progesterone production was determined using an EIA kit. *P o 0.05 vs. control, **P o 0.01 vs. FSK PDK1 or through a yet unknown pathway. Activated Akt then activates mTORC1 and its downstream targets, 4EBP1 and S6K1, leading to transcriptional and/or translational activation of progesterone synthesis related genes. In this context, we have previously shown, using ChIP assays, that hCG increases the recruitment of cAMP response elementbinding protein to the proximal promoter of CYP17A1 gene, and that this increase was significantly reduced by rapamycin [42] . It is likely that the expression of other steroidogenic enzymes might also be activated through a similar mechanism.
In summary, we show here that mTOR signaling plays a crucial role in progesterone production in human granulosa lutein cells in response to stimulation by LH/hCG. This finding may explain the clinical observation that renal transplant patients treated with rapamycin (also called sirolimus) for immunosuppression showed diminished testosterone production, while their LH and FSH levels remained high [43, 44] . Similarly, it has been reported that female renal transplant patients treated with rapamycin exhibit gonadal dysfunction and infertility, with increased FSH and LH and decreased progesterone levels [45] . Interestingly, menses returned and hormone levels returned to normal after cessation of rapamycin [45] . The present study, in addition to providing new information on the signaling pathways regulating progesterone production in granulosa lutein cells, also provides a mechanistic explanation for these clinical findings and may assist in patient selection and counseling.
